Analysis of Liquidity Ratios
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
AstraZeneca PLC, liquidity ratios
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Current ratio | 0.96 | 1.27 | 1.37 | 1.49 | 1.50 | |
| Quick ratio | 0.75 | 1.02 | 1.08 | 1.25 | 1.16 | |
| Cash ratio | 0.41 | 0.62 | 0.61 | 0.75 | 0.75 |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | AstraZeneca PLC current ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | AstraZeneca PLC quick ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | AstraZeneca PLC cash ratio improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014. |
Current Ratio
AstraZeneca PLC, current ratio calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 16,697) | 20,335) | 19,048) | 23,506) | 25,131) | |
| Current liabilities | 17,330) | 16,051) | 13,903) | 15,752) | 16,787) | |
| Liquidity Ratio | ||||||
| Current ratio1 | 0.96 | 1.27 | 1.37 | 1.49 | 1.50 | |
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Current ratio = Current assets ÷ Current liabilities
= 16,697 ÷ 17,330 = 0.96
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | AstraZeneca PLC current ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
Quick Ratio
AstraZeneca PLC, quick ratio calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Trade receivables, less amounts provided for doubtful debts | 4,762) | 5,514) | 5,696) | 6,630) | 6,247) | |
| Other receivables | 1,072) | 794) | 835) | 1,237) | 671) | |
| Other investments | 795) | 796) | 823) | 4,248) | 1,482) | |
| Cash and cash equivalents | 6,360) | 9,217) | 7,701) | 7,571) | 11,068) | |
| Total quick assets | 12,989) | 16,321) | 15,055) | 19,686) | 19,468) | |
| Current liabilities | 17,330) | 16,051) | 13,903) | 15,752) | 16,787) | |
| Liquidity Ratio | ||||||
| Quick ratio1 | 0.75 | 1.02 | 1.08 | 1.25 | 1.16 | |
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 12,989 ÷ 17,330 = 0.75
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | AstraZeneca PLC quick ratio deteriorated from 2012 to 2013 and from 2013 to 2014. |
Cash Ratio
AstraZeneca PLC, cash ratio calculation, comparison to benchmarks
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Other investments | 795) | 796) | 823) | 4,248) | 1,482) | |
| Cash and cash equivalents | 6,360) | 9,217) | 7,701) | 7,571) | 11,068) | |
| Total cash assets | 7,155) | 10,013) | 8,524) | 11,819) | 12,550) | |
| Current liabilities | 17,330) | 16,051) | 13,903) | 15,752) | 16,787) | |
| Liquidity Ratio | ||||||
| Cash ratio1 | 0.41 | 0.62 | 0.61 | 0.75 | 0.75 | |
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Zoetis Inc. | — | — | — | — | — | |
Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).
1 2014 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 7,155 ÷ 17,330 = 0.41
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | AstraZeneca PLC cash ratio improved from 2012 to 2013 but then deteriorated significantly from 2013 to 2014. |